Table 3.
Characteristics of AML-patients and healthy volunteers included in this study are presented.
| Age at | Subtype | Blasts | Conducted | Conducted | |||||
|---|---|---|---|---|---|---|---|---|---|
| Stage | Pat. # | dgn. | Sex | FAB | Blast Phenotype (CD) | in PB % | DC/DCleu-Cultures | Experiments | |
| AML | First Diagnosis | P1419 | 64 | f | p/M1 | 34, 117, 33, 15, 13 | 93 | PBMC | |
| P1426 | 61 | f | s/M5 | 34, 117, 64, 33, 13 | 40 | PBMC, WB | MLCWB, MLCWB-DC, CTX | ||
| P1430 | 79 | m | p/M5 | 34, 117, 33, 13 | 70 | PBMC, WB | MLCWB, MLCWB-DC, CTX | ||
| P1432 | 34 | m | p/M5 | 34, 64, 33, 13 | 81 | PBMC, WB | MLCWB, MLCWB-DC, CTX | ||
| P1434 | 61 | f | s/n.d. | 34, 117, 64, 56, 33, 13, 7 | 61 | PBMC, WB | MLCWB, MLCWB-DC, CTX | ||
| P1439 | 61 | f | s/M5 | 34, 117, 33, 13 | 17 | PBMC, WB | MLCWB, MLCWB-DC | ||
| P1441 | 60 | m | s/M4 | 117, 65, 64, 33, 13, 14, | 81 | PBMC, WB | MLCWB, MLCWB-DC, CTX | ||
| P1442 | 73 | f | s/M4 | 117, 138, 61, 33 | 14 | PBMC, WB | MLCWB, MLCWB-DC, CTX | ||
| P1443 | 64 | m | p/n.d. | 34, 117, 33, 13 | 50 | PBMC, WB | |||
| P1447 | 21 | m | p/M5 | 56, 33, 45 | 65 | WB | CTX | ||
| P1449 | 78 | m | s/n.d. | 15, 65, 64, 45, 4 | 62 | WB | MLCWB, MLCWB-DC, CTX | ||
| P1452 | 44 | m | p/n.d. | 34, 117, 45, 33, 13 | 55 | PBMC, WB | CTX | ||
| P1453 | 54 | f | p/M4 | 15, 64, 56, 33, 14 | 52 | PBMC, WB | MLCWB, MLCWB-DC | ||
| P1454 | 60 | f | s/n.d. | 34, 117, 61, 20 | 33 | WB | |||
| P1459 | 54 | m | p/M4 | 56, 64, 38, 33, 11c, 11b | 14 | PBMC, WB | MLCWB, MLCWB-DC, CTX | ||
| P1460 | 78 | f | p/M4 | 15, 34, 117 | 68 | PBMC, WB | MLCWB, MLCWB-DC | ||
| P1462 | 49 | f | p/M5 | 34, 56, 64, 45, 33, 13 | 60 | WB | |||
| P1466 | 47 | f | p/n.d. | 34, 117, 33, 15, 13 | 15 | PBMC | |||
| P1471 | 40 | m | p/M1 | 34, 117, 33, 13 | 69 | PBMC, WB | |||
| P1472 | 33 | f | p/M2 | 117, 34, 15, 13 | 30 | WB | |||
| Relapse Before or after HSCT | P1474 | 70 | m | p/n.d. | 117, 34, 56, 33 | 80 | PBMC, WB | ||
| P1475 | 77 | m | s/n.d. | 117, 34, 33, 13 | 20 | PBMC, WB | |||
| P1455 | 63 | m | s/n.d. | 34, 117, 13 | 12 | WB | |||
| P1463 | 60 | f | s/n.d. | 34, 56, 33, 13, 2 | 8 | PBMC, WB | CTX | ||
| P1469 | 49 | m | p/M4 | 34, 117, 65, 33, 13 | 94 | PBMC | |||
| P1470 | 67 | m | p/n.d. | 56, 117, 34, 33, 13, | 9 | PBMC, WB | |||
| Persisting Disease | P1464 | 72 | m | s/n.d. | 34, 117, 71, 20 | 44 | PBMC, WB | MLCWB, MLCWB-DC, CTX | |
| P1467 | 59 | f | s/n.d. | 34, 117, 33, 15, 13 | 30 | PBMC, WB | |||
| P1468 | 66 | m | p/n.d. | 117, 56, 34, 33 | 75 | PBMC, WB | |||
| Healthy | P1418 | 22 | m | PBMC, WB | |||||
| P1420 | 26 | f | PBMC, WB | ||||||
| P1421 | 27 | f | PBMC | ||||||
| P1422 | 20 | f | PBMC, WB | ||||||
| P1428 | 56 | f | PBMC, WB | ||||||
| P1429 | 22 | f | WB | ||||||
| P1436 | 25 | m | PBMC, WB | ||||||
| P1438 | 31 | f | PBMC, WB | ||||||
| P1445 | 27 | f | PBMC, WB | ||||||
| P1446 | 25 | m | PBMC, WB |
Pat.# Patient’s number; f female; m male; p primary AML; s secondary AML; FAB French-American-British classification; PB peripheral blood; n.d. no data; dgn. diagnosis; PBMC peripheral blood mononuclear cells; WB whole blood; HSCT hematopoietic stem cell transplantation; MLCWB mixed lymphocyte culture with WB not preincubated with DC/DCleu-generating protocols; MLCWB-DC mixed lymphocyte culture with WB preincubated with DC/DCleu-generating protocols; CTX cytotoxicity (fluorolysis) assay; bold blasts markers used to detect DCleu at the day of harvest